Capricor Therapeutics, Inc. (NASDAQ:CAPR) Receives $40.82 Average Price Target from Analysts

Shares of Capricor Therapeutics, Inc. (NASDAQ:CAPR) have been given an average rating of “Moderate Buy” by the ten ratings firms that are currently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation and nine have assigned a buy recommendation to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $40.8182.

Several analysts recently issued reports on CAPR shares. Alliance Global Partners reaffirmed a “buy” rating on shares of Capricor Therapeutics in a report on Wednesday, December 3rd. Oppenheimer boosted their target price on shares of Capricor Therapeutics from $22.00 to $54.00 and gave the stock an “outperform” rating in a research report on Monday, December 8th. Maxim Group upped their price target on shares of Capricor Therapeutics from $25.00 to $50.00 and gave the company a “buy” rating in a report on Thursday, December 4th. HC Wainwright raised their price target on Capricor Therapeutics from $24.00 to $60.00 and gave the company a “buy” rating in a research report on Wednesday, December 3rd. Finally, Piper Sandler reiterated an “overweight” rating and issued a $45.00 price objective (up from $20.00) on shares of Capricor Therapeutics in a research note on Wednesday, December 10th.

Capricor Therapeutics Stock Performance

Shares of CAPR stock opened at $27.89 on Tuesday. The stock’s 50 day simple moving average is $25.66 and its 200 day simple moving average is $14.87. Capricor Therapeutics has a twelve month low of $4.30 and a twelve month high of $40.37. The company has a market capitalization of $1.28 billion, a price-to-earnings ratio of -15.49 and a beta of 0.38.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Farther Finance Advisors LLC bought a new stake in shares of Capricor Therapeutics in the third quarter valued at approximately $28,000. Parkside Financial Bank & Trust acquired a new position in Capricor Therapeutics during the 3rd quarter valued at $36,000. Russell Investments Group Ltd. raised its stake in Capricor Therapeutics by 122.2% during the 3rd quarter. Russell Investments Group Ltd. now owns 5,066 shares of the biotechnology company’s stock valued at $37,000 after purchasing an additional 2,786 shares during the last quarter. ACT Capital Management LLC bought a new stake in Capricor Therapeutics in the 4th quarter valued at $43,000. Finally, GoalVest Advisory LLC acquired a new stake in Capricor Therapeutics in the 4th quarter worth $59,000. 21.68% of the stock is currently owned by institutional investors and hedge funds.

About Capricor Therapeutics

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.